Alkem Laboratories appoints Gopal Kothari as chief financial officer
- Management change
- Pharmaceuticals

Alkem Laboratories (NSE: ALKEM) has appointed Gopal Kothari as its Chief Financial Officer and Key Managerial Personnel, it said in a filing on 12 Nov 2026. The appointment takes effect from 02 Dec 2026 and runs for as long as he remains in the company's employment.
Appointment details and background
The Board approved the appointment at a meeting held on 12 Nov 2026, which began at 11.30 a.m. and ended at 01.40 p.m. It followed a recommendation from the Nomination and Remuneration Committee and approval from the Audit Committee.
Kothari has over 24 years of experience in financial planning and analysis, business partnering, cash flow management, business finance, cost management, taxation, management reporting, finance control and dealing with boards of directors. He is a qualified chartered accountant and company secretary and holds a B. Com. (Honours) degree. The company states that there is no disclosed relationship between him and other directors.
Context within recent filings
The appointment is one of several management changes disclosed this month. On 3 Nov 2026 the company said it had appointed Dr. Amrut Naik as Chief Executive Officer from 11 Nov 2026, and on 8 Nov 2026 it reported the incorporation of a joint venture subsidiary in Saudi Arabia.
What the CFO appointment means for Alkem Laboratories' shareholders
The filing records a change in the company's senior finance leadership, with no financial amount attached. The reason for the change, whether Kothari replaces a previous officer, whether he is an internal or external appointee, and his remuneration are not stated.
The next dated step is the effective date of 02 Dec 2026.
At a glance
| Item | Detail |
|---|---|
| Officer | Gopal Kothari, Chief Financial Officer and Key Managerial Personnel |
| Board approval | 12 Nov 2026 |
| Effective date | 02 Dec 2026 |
| Term | As long as he is in the company's employment |
| Recommended by | Nomination and Remuneration Committee, with Audit Committee approval |
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
